medigraphic.com
Órgano Oficial de la Sociedad Mexicana de Angiología y Cirugía Vascular

2014, Number 1

Next >>

Rev Mex Angiol 2014; 42 (1)

Tratamiento conservador en pacientes con enfermedad arterial periférica en estadio Rutherford 1-5

González-Mendoza B

Language: Spanish
References: 16
Page: 4-7
PDF size: 186.97 Kb.


ABSTRACT

Aim. To demonstrate what the use of cilostazol in symptomatic patients with peripheral arterial disease (PAD) may improve short-term clinical stage.
Material and methods. We performed a cohort study during the period October 2011 to July 2013, in the office located in Metepec, Estado de México, identifying patients with (PAD) who had intermittent claudicaction, critical limb ischemic (CLI) and punctate ischemic ulcers, who had been revascularized of the limb contralateral limb symptoms in non revascularized with high surgical risk to under go open surgery or endovascular procedure and those who had no financial resources for such intervention.
Results. In 67 patients, 38 men (56.7%) and 29 women (43.3%), with a mean age of 72.6 years, with a history of importance: 37.3% smoking, 73.1% diabetes and 56.7% hypertension. Reduction was found Rutherford in 87% of patients, in the subgroup of patients with diabetes there was a reduction of Rutherford 5 to Rutherford 1 and patients without diabetes of Rutherford 4 to Rutherford 2. The presentation of adverse effects with the use of cilostazol was 19% of patients.
Conclussion. The results of this study showed that cilostazol may reduced the severity of PAD in patients not candidates for revascularization with few adverse effects, even in patients with stage Rutherford 4 and 5.


REFERENCES

  1. Hawkey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295: 547-53.

  2. Feringa HH, Jax JJ, van Waning VH, et al. The long-term prognostic value of resting and postexercise ankle-brachial index. Arch Intern Med 2006; 166: 529-35.

  3. Selvin E. Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999- 2000. Circulation 2004; 110: 738-43.

  4. Muluk SC, Muluk VS, Kelley ME, et al. Outcome events in patients with claudication: a 15 year study in 2777 patients. J Vasc Surg 2001; 33: 251-7.

  5. Stewart KJ, Hiatt WR, Regensteiner JG, et al. Exercise training for claudication. N Engl J Med 2002; 347: 1941-51.

  6. Makris GC, Lattimer CR, Lavida A, et al. Availability of Supervised Exercise Programs and the Role of Structured Home-based Exercise in Peripheral Arterial Disease. Eur J Vasc Endovasc Surg 2012; 44(6): 569-75.

  7. Gresele P, Migliacci R, Arosio E, et al. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. J Vasc Surg 2012; 56(6): 1622-8.

  8. Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg 2012; 55(5): 1346-54.

  9. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl. S): S5-S67.

  10. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery, Society for Vascular Surgery, Society for Cardiovascular Angiography and Intervention, Society for Vascular Medicine and Biology, Society for Interventional Radiology and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47: 1239-312.

  11. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-30.

  12. Barnett AH, Bradbury AW, Brittenden J, et al. The role of cilostazol in the treatment of intermittent claudication. Curr Med Res Opin 2004; 20: 1661-70.

  13. Regensteiner J, Ware JJ, McCarthy W, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50: 1939-46.

  14. The I.C.A.I. Group: Long-term mortality as predictors in patients with critical leg ischemia. Eur J Vasc Endovasc Surg 1997; 14: 91-5.

  15. Pande RT, Perlstein TS, Beckman JA, et al. Secondary Prevention and Mortality in Peripheral Artery Disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124: 17-23.

  16. Moneta GL. Secondary Prevention and Mortality in Peripheral Artery Disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124:17-23




2020     |     www.medigraphic.com